Italy
Dompé, a private and family-owned biopharmaceutical company, boasts over 130 years of independent history, dedicated to transforming treatments for ophthalmic, neurological, and pain conditions through groundbreaking science. This established firm has pioneered the therapeutic potential of nerve growth factor (NGF), advancing first-in-class, disease-modifying therapies that address the root causes of nerve damage rather than just alleviating symptoms.
Underpinning their success is a commitment to integrating Nobel Prize-winning science into practice, exemplified by the approval of the first topical biologic for a rare neurotrophic eye disease. Their research-driven approach combines scientific rigor with agility, underscoring their focus on developing innovative biologics and new delivery platforms to tackle difficult diseases.
Dompé's independence ensures sustained innovation and a robust integration of research, manufacturing, and commercialization. Committed to patient care and fostering scientific talent, their mission is to unleash the full potential of NGF and other molecules in reshaping nervous system treatments.
